Overview


According to FutureWise analysis, the market for Recombinant Erythropoietin is expected to grow with a CAGR of 2.22% over the forecast period 2023-2031, and reach a market value of US$ 8.35 Billion by 2031. 

Recombinant erythropoietin, commonly called EPO, is a lab-engineered version of the natural hormone erythropoietin, initially produced by the kidneys. This hormone plays a pivotal role in overseeing the generation of red blood cells within the confines of the bone marrow. Through genetic engineering methods, recombinant EPO can be manufactured on a large scale in laboratory settings.

Erythropoietin primarily stimulates the growth and specialization of precursor cells for red blood cells, known as erythroid progenitor cells. These precursor cells ultimately develop into fully operational red blood cells, serving a vital function in oxygen transport throughout the body. By bolstering the production of red blood cells, recombinant EPO effectively addresses anemia—a condition characterized by insufficient red blood cells or hemoglobin. The introduction of recombinant EPO has marked a significant breakthrough in treating anaemia, especially for individuals grappling with chronic kidney disease (CKD), which may lead to reduced natural erythropoietin production. Furthermore, it finds application in patients undergoing specific medical treatments, such as chemotherapy, where anemia is a prevalent side effect. The administration of recombinant EPO is typically done through injections, either subcutaneously or intravenously, contingent on the specific formulation and the patient's condition.

FutureWise Market Research has published a report that provides an insightful analysis of Recombinant Erythropoietin Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Recombinant Erythropoietin Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Amgen Inc.
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Pfizer Inc.
  • Roche Holding AG
  • Novartis AG
  • Biocon Limited
  • Teva Pharmaceutical Industries Ltd.
  • LG Chem Ltd.
  • Sandoz International GmbH (a subsidiary of Novartis AG)
  • Intas Pharmaceuticals Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Celltrion Inc.
  • 3SBio Inc.
  • CJ CheilJedang Corporation
  • BioSidus SA

(Note: The list of the major players will be updated with the latest market scenario and trends)

The increasing prevalence of anemia, attributed to aging populations and chronic diseases, drives the demand for recombinant erythropoietin. It is a key therapeutic option for addressing anemia associated with various medical conditions and creates vast opportunities for market growth. Recombinant erythropoietin is a cornerstone in managing anemia related to chronic kidney disease. With a growing population affected by chronic kidney disease, the demand for erythropoietin in this patient group continues to rise and thus propels the market. Advanced developments in biotechnology and genetic engineering techniques enhance the production and formulation of recombinant erythropoietin, contributing to its availability and effectiveness and enhancing the market's revenue growth.

However, recombinant erythropoietin is associated with potential risks, including elevated red blood cell counts, which may lead to complications like blood clots and hence acts as a restaurant for market growth. Stringent regulatory processes and approval requirements for biopharmaceuticals, including erythropoietin, can pose market entry and commercialization challenges, potentially limiting its availability. The development of alternative treatments for anemia, such as iron supplementation, erythropoiesis-stimulating agents (ESAs), and novel drug classes, introduces competition to the erythropoietin market.

By Type of Recombinant Erythropoietin:

  • Epoetin Alfa
  • Darbepoetin Alfa

By Route of Administration

  • Subcutaneous
  • Intravenous

By Indication

  • Anemia Associated with Chronic Kidney Disease (CKD)
  • Cancer-Related Anemia
  • HIV-Associated Anemia
  • Others

By End User

  • Hospitals and Clinics
  • Dialysis Centers
  • Oncology Centers
  • Others

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to well-established healthcare infrastructure and a high prevalence of chronic kidney disease and cancer; large patient population requiring rEPO therapy, stringent regulatory frameworks, and reimbursement systems also influence the market growth.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Recombinant Erythropoietin Market By Type of Recombinant Erythropoietin, By Route of Administration, By Indication, By End User, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Recombinant Erythropoietin Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Recombinant Erythropoietin Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Recombinant Erythropoietin Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Recombinant Erythropoietin Market, By Type of Recombinant Erythropoietin Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Epoetin Alfa
      2. Darbepoetin Alfa
  • 8.  Recombinant Erythropoietin Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Subcutaneous
      2. Intravenous
  • 9.  Recombinant Erythropoietin Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Anemia Associated with Chronic Kidney Disease (CKD)
      2. Cancer-Related Anemia
      3. HIV-Associated Anemia
      4. Others
  • 10.  Recombinant Erythropoietin Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Hospitals and Clinics
      2. Dialysis Centers
      3. Oncology Centers
      4. Others
  • 11.  North America Recombinant Erythropoietin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.  Latin America Recombinant Erythropoietin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.  Europe Recombinant Erythropoietin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.  Asia Pacific Recombinant Erythropoietin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031  

  • 15.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 17.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Amgen Inc.
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Johnson & Johnson (Janssen Pharmaceuticals)
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Pfizer Inc.
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Roche Holding AG
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Novartis AG
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Biocon Limited
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Teva Pharmaceutical Industries Ltd.
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. LG Chem Ltd.
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Sandoz International GmbH (a subsidiary of Novartis AG)
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Intas Pharmaceuticals Ltd.
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Dr. Reddy's Laboratories Ltd.
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Celltrion Inc.
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. 3SBio Inc.
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. CJ CheilJedang Corporation
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. BioSidus SA
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview

  • 18.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients